TSHA

NASD Taysha Gene Therapies, Inc.
Oct 14, 2026 · 2:03 AM ET EOD Market Closed

$3.58 ↑ +0.00 (+0.00%) Trading Up from the previous close of $3.58, $0.55 below the day’s high of $4.13

YTD change
-34.91%
vs 20-day SMA
-25.00%
vs 200-day SMA
-33.93%

Price ranges

Previous day
$4.13 $4.56
open $4.46 close $4.14
-$0.32 (-7.17%)
Today
$3.55 $4.13
open $4.09 now $3.58
-$0.51 (-12.47%)
Past week
$4.13 $4.57
from $4.49 now $3.58
-$0.91 (-20.27%)
Past month
$4.13 $5.46
from $5.01 now $3.58
-$1.43 (-28.54%)
This year
$3.55 $7.30
from $5.50 now $3.58
-$1.92 (-34.91%)

Price & Performance

-0.84 (-19.00%) / 6M

$3.31$4.62$5.94$7.25Apr 13Jul 14Oct 13

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor
  • The stock is 89.3% away from all-time highs of $33.35
  • TSHA is down 35% since the beginning of the year
  • TSHA is down 29% over the past 12 months
  • TSHA is down 29% over the past 1 month
  • 18% of all TSHA investors are betting against TSHA

TSHA reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -29.1%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.13
Earnings momentum -1.1% Quarterly EPS growth
Quarterly change -1.1%

Valuation

P/E ratio N/A
Enterprise value $1.1B
Beta 3.48

Balance sheet & scale

IncomeN/A
Revenue$5.5M
Cash$455.4M
Debt$56.9K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $1.2B

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $412.84 -1.13%
MRNA Moderna, Inc. $216.25 +1.17%
RVMD Revolution Medicines, Inc. $188.44 -2.84%
ROIV Roivant Sciences Ltd. $33.35 -3.58%
BNTX BioNTech SE Sponsored ADR $89.01 -7.13%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.